Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands (NEURIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02602275
Recruitment Status : Completed
First Posted : November 11, 2015
Last Update Posted : January 28, 2016
Sponsor:
Information provided by (Responsible Party):
Biologische Heilmittel Heel GmbH

Brief Summary:
The purpose of this study is to explore the effect of Neurexan® on the brain response when participants undergo an emotional stressful condition in verum compared to placebo.

Condition or disease Intervention/treatment Phase
Acute Stress Reaction Drug: Neurexan® Other: Placebo Phase 2

Detailed Description:
A randomized placebo-controlled, double-blind, two-period crossover study with an explorative design. 40 healthy males aged 31-59 years will be included in the study. Participant allocation to either Neurexan® or Placebo at study start is randomized with a ratio of 1:1, i.e. 20 Neurexan® first to 20 Placebo first individuals. Participants receive totally three tablets of either Neurexan® or Placebo per treatment period orally.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands - A Randomized, Placebo-controlled, Double-blind, Cross-over Trial of Mode of Action and Response Prediction by Functional Magnetic Resonance Imaging MRI
Study Start Date : August 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Neurexan®
0.6 mg / tablet, 3 tablets, 40-60 minutes before the second MRI Intervention: Drug: Neurexan®
Drug: Neurexan®
There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the experimantal arm participants will receive verum on DAY1/PERIOD 1 and will receive placebo on DAY2/PERIOD 2.

Placebo Comparator: Placebo
3 tablets, 40-60 minutes before the second MRI
Other: Placebo
There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the comparator arm participants will receive placebo on DAY1/PERIOD 1 and will receive verum on DAY2/PERIOD 2.




Primary Outcome Measures :
  1. Reduced amygdala responsiveness measured by negative face to form contrasts in the Hariri task (Hariri et. al., 2000; Hariri et. al., 2003) after verum versus placebo condition [ Time Frame: Day 1 and Day 2 ]
    Primary Outcome 1: Effect of drug, driven by significantly smaller amygdala activations in the contrast (negative faces vs forms) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.

  2. Reduced functional connectivity density (FCD) in amygdala after verum versus placebo condition during rest. [ Time Frame: Day 1 and Day 2 ]
    Primary Outcome 2: Interaction of time and drug, driven by significantly greater reductions of amygdala functional connectivity density (FCD) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.

  3. Reduced whole brain functional connectivity of amygdala after verum versus placebo condition during rest. [ Time Frame: Day 1 and Day 2 ]
    Primary Outcome 3: Interaction of time and drug, driven by significantly greater changes (smaller and greater, two sided effects because of inclusion of top down and bottom up processes in different regions) of amygdala seeded connectivities in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the whole brain.

  4. Reduced local resting state activity of amygdala after verum versus placebo condition. [ Time Frame: Day 1 and Day 2 ]
    Primary Outcome 4: Interaction of time and drug, driven by significantly greater reductions of amygdala ALFF in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.

  5. Increased effective connectivity from frontal cortex to amygdala during Hariri experiment after verum versus placebo condition. [ Time Frame: Day 1 and Day 2 ]
    Primary Outcome 5: Influence of drug on directed connectivity in an effective connectivity model (DCM) from ventral prefrontal cortex (vPFC) towards amygdala, driven by positive effects of verum on directed negative effective (top down) connectivity from vPFC to amygdala. Significance for the modulating effect of drug on effective connectivity is accepted for a p level of 0.05, for a winning model selected based on Bayesian information criterion (BIC) across all subjects and scans (verum and placebo) (Sladky et al 2013).

  6. Reduced stress network activation during stress (MIST) in verum relative to placebo. [ Time Frame: Day 1 and Day 2 ]
    Primary Outcome 6: Effect of drug, driven by significantly smaller activations in anterior cingulate cortex, medio-orbitofrontal cortex, hippocampus, amygdala, and hypothalamus in the contrast (hard vs easy) in verum compared to placebo conditions. Significance level is 0.05, corrected for multiple comparisons in the search volume which is anatomically defined by the AAL (Automated Anatomical Labelling Atlas) coordinates.


Secondary Outcome Measures :
  1. Normalized EEG frontal frequency changes associated with normalized HRV in verum relative to placebo conditions. [ Time Frame: Day 1 and Day 2 ]
  2. High morning cortisol and alpha-amylase level predicts increased subjective stress response (VAS, STAI-XI), effect which is reversed in verum but not in placebo condition. [ Time Frame: Day 1 and Day 2 ]
    Individual cortisol and alpha-amylase level at 8 timepoints during the MRI visits, VAS (tensions and nervousness) at 7 timepoints, and STAI-X1 at 6 timepoints will be computed as the area under the curve. The relation between change in cortisol, VAS (tension and nervousness) and personality traits (TCI), coping to stress (ABI, FKK), self-esteem (Rosenberg Self-Esteem), and childhood traumatic experiences (CTQ) will be investigated by the use of non-parametric correlations analysis. Changes in subject reported outcome instruments and stress response by morning cortisol and alpha amylase will be evaluated within the framework of formal crossover analyses. Due to unknown distributions, the analysis will be of nonparametric nature.

  3. Reduced subjects stress perception as assessed with STAI-XI, VAS after MIST task in verum relative to placebo condition. [ Time Frame: Day 1 and Day 2 ]
    The analysis is already described under point "Outcome 8" and "Outcome 10" of secondary outcome measures.

  4. Personality traits assessed with TCI predicted stress response. [ Time Frame: Screening Visit ]
    It will be investigated how personality traits (TCI), anxiety level (STAI), depressive symptoms (BDI-II), self-esteem, subject's coping strategies as well as cognitive processes predict stress response and the relation with Neurexan® efficiency. Regression analyses will be conducted on resting state functional connectivity in placebo and verum conditions. These exploratory analyses are hypothesis generating in order to confine follow up investigations.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   31 Years to 59 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male
  2. Age between ≥31 to ≤59 years
  3. Fluent in German language
  4. Nonsmoker
  5. Able to understand the explanations and instructions given by the study physician
  6. Willing to adhere to the prohibitions and restrictions specified in this protocol
  7. Healthy on the basis of clinical laboratory tests, physical examination, medical history, vital signs performed at Screening Visit
  8. Magnetic Resonance Imaging (MRI) compatible
  9. Participants must have signed a written informed consent document prior to any study procedure indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
  10. Trier Inventory for Chronic Stress (TICS) Score ≥ 9 and ≤ 36
  11. Perceived Stress Scale (PSS) > 9

Exclusion Criteria:

  1. Current or past history of psychotic features or a diagnosis of any psychiatric disorder as defined in the Diagnostic and Statistical Manual of Mental Disorder 4th edition (DSM-IV) Axis I (recurrent major depression, panic disorder, social phobia, obsessive-compulsory disorder; alcohol dependency; schizophrenia and mania)
  2. History of depressive episodes during the last 3 months prior to Screening Visit
  3. Use of any psychotropic medication or suffering from severe psychiatric illness during the last 3 months prior to Screening Visit
  4. Intake of prescription drugs for sleeping disorders or nervousness within one month prior to Screening Visit
  5. Intake of over the counter (OTC) medication for the treatment of sleeping disorders or nervousness within the last (one) week prior to Screening Visit
  6. High chronic stress as verified with the TICS-SSCS (> 36)
  7. Low chronic stress as verified with the TICS-SSCS (< 9) and PSS ≤ 9
  8. Participants with Blood Pressure (BP) ≥ 160/100 on day 0 and at randomization
  9. Participants with treated hypertension
  10. Known allergies and/or hypersensitivity to ingredients of Neurexan® (Passiflora incarnata, Avena sativa, Coffea arabica, Zincum isovalerianicum, lactose monohydrate, magnesium stearate) or Placebo (Lactose monohydrate, magnesium stearate)
  11. Known Lactose intolerance
  12. Use of any psychological stress-management intervention within the last 4 weeks prior to Screening Visit
  13. History of substance, drug, including nicotine, or alcohol abuse within the preceding 3 months prior to Screening Visit
  14. Alcohol, drug, nicotine intake within the last 24 hours before day 0 and at randomization - confirmed by positive screening tests
  15. Body Mass Index (BMI) > 30 kg/m2
  16. Works regularly nights shifts
  17. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic or hematologic disease as defined by clinical screening interview
  18. Any somatic disease or other condition the Investigator or their duly assigned representatives believes could affect the ability of the individual to complete the study or the interpretation of the study results
  19. Participants with medical illness that may have influenced brain morphology and/or physiology (e.g. uncontrolled hypertension, diabetes)
  20. Participants with a history of one or more seizures without a clear and resolved aetiology
  21. Participants with claustrophobia
  22. Participants with tinnitus
  23. Clinically significant acute illness within 7 days prior to randomization
  24. Presence of metallic (ferromagnetic) implants (heart pacemaker, aneurysm clips), tattoos or piercings
  25. Have received an experimental drug or used an experimental medical device (participation in any other clinical trial) within the last 30 days before study inclusion
  26. Participants whose ability to speak for themselves lacks or can be doubted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02602275


Locations
Layout table for location information
Germany
Clinical Affective Neuroimaging Laboratory (CANLAB)
Magdeburg, Germany
Sponsors and Collaborators
Biologische Heilmittel Heel GmbH
Investigators
Layout table for investigator information
Principal Investigator: Martin Walter, PD Dr Med. Clinical Affective Neuroimaging Laboratory, Univ. Magdeburg, Germany
Layout table for additonal information
Responsible Party: Biologische Heilmittel Heel GmbH
ClinicalTrials.gov Identifier: NCT02602275    
Other Study ID Numbers: NEURIM, C1501
First Posted: November 11, 2015    Key Record Dates
Last Update Posted: January 28, 2016
Last Verified: January 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Stress
Stress Disorders, Traumatic, Acute
Fractures, Bone
Wounds and Injuries
Stress Disorders, Traumatic
Trauma and Stressor Related Disorders
Mental Disorders